Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Erbb2 interacting protein (ERBIN)
- Target
- ERBIN
- Molecular classification
- Adapter/scaffolding protein, LAP (leucine-rich repeat and PDZ domain) family
01
Overview
Erbb2 interacting protein (ERBIN) is a large scaffolding protein of the LAP family containing 17 leucine-rich repeats and a single PDZ domain. ERBIN is primarily known for binding the unphosphorylated form of the ErbB2 receptor (HER2/ERBB2) at Tyr-1248, helping regulate its localization and stabilization in epithelial cells. Through this, ERBIN modulates ERBB2-dependent signaling, potentially acting as a tumor suppressor by disrupting Ras-Raf interaction and negatively regulating oncogenic signaling. ERBIN also inhibits NOD2-mediated NF-κB signaling, thereby moderating inflammation. Clinical relevance is suggested by associations with immunodeficiency and inflammation when ERBIN is deficient, but it is not a current direct drug target.
- Other names
- ErbinERBB2IPKIAA1225LAP2Densin-180-like proteinProtein LAP2densin-180-like proteinERBB2-interacting proteinHEL-S-78epididymis secretory protein Li 78
02
Biological functions
Scaffolding and localization of ERBB2 receptor in epitheliaNegative regulation of Ras-Raf signaling pathwayInhibition of NOD2-dependent NF-κB signaling and pro-inflammatory cytokine secretion
03
Disease associations
Cancer (tumor suppressive potential via negative regulation of Ras-Raf signaling)Immunodeficiency (autosomal dominant combined immunodeficiency due to Erbin deficiency)Inflammatory disease (immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia)
Beyond the preview
Go deeper on Erbb2 interacting protein (ERBIN).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Erbb2 interacting protein (ERBIN).